Kamil Ali-Jackson Sells Shares of RIGL
Kamil Ali-Jackson sold 2,500 shares of RIGL in a planned transaction on June 22, 2026.
Key Points
- Kamil Ali-Jackson sold 2,500 shares of RIGL on June 22, 2026, at $35.00 each, totaling $87,500 in a planned sale.
- Shares of RIGL traded at $36.79 on Thursday with notable institutional activity from BlackRock and Armistice Capital.
- Analysts from HC Wainwright & Co. and Citigroup have maintained buy ratings with targets up to $81.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kamil Ali-Jackson, an insider at RIGL, sold 2,500 shares of the company on June 22, 2026. This planned transaction was executed at an average price of $35.00 per share, amounting to a total value of $87,500.
Other Institutional Activity in RIGL
BlackRock, Inc. grew its holdings in RIGL by 104,697 shares, bringing its total to 1,768,907 shares valued at approximately $47.83 million. Armistice Capital, LLC significantly increased its stake by 444,000 shares, resulting in a total of 1,280,000 shares worth about $34.61 million, a 53.1% increase. Vanguard Capital Management LLC opened a new position with 764,193 shares valued at $20.66 million. Meanwhile, Acadian Asset Management LLC added 172,822 shares, ending with 666,426 shares worth $18.01 million, marking a 35.0% increase.
Rigel Pharmaceuticals, Inc. Stock Down 20.8%
On Thursday, RIGL shares were trading at $36.79. The stock has been experiencing some fluctuations with a current market cap and other specific financial metrics not provided. However, the institutional interest suggests a dynamic trading environment for RIGL.
$RIGL stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Rigel Pharmaceuticals, Inc.
In addition to Kamil Ali-Jackson's sale, several other insiders have been active. On June 17, 2026, Dean Schorno, EVP & Chief Financial Officer, along with Raymond Furey, David Santos, Raul Rodriguez, and Lisa Rojkjaer, acquired shares without a specified price, indicating potential confidence in the company's future performance.
Analysts Set New Price Targets
HC Wainwright & Co. reiterated a buy rating for RIGL on May 22, 2026, with a price target of $57.00. Citigroup maintained its buy rating across multiple reports, with the highest target set at $81.00 on May 13, 2026. These ratings reflect a positive outlook from analysts on RIGL's potential.
Bottom Line
The recent insider sale by Kamil Ali-Jackson, along with substantial institutional activity, highlights the active trading environment surrounding RIGL. Analysts remain optimistic, with several maintaining buy ratings and setting ambitious price targets. As always, it's important to remember that 13F filings and insider transactions are backward-looking and might not reflect the most current positions.
Get Rigel Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RIGL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.